Zonisamide safety was evaluated based on a postmarketing surveillance study of patients treated for 1-3 years. Nine hundred twenty-eight children and 584 adult (ages 1 month to 79 years), including 372 newly-diagnosed patients, received zonisamide for partial and generalized epilepsies. Of the intractable patients, 1088 received zonisamide in combination with other antiepileptic drugs (AED), an...

CONTEXT Zonisamide is a marketed antiepileptic drug that has serotonergic and dopaminergic activity in addition to blockade of sodium and calcium channels. Weight loss was an adverse effect associated with zonisamide treatment in epilepsy clinical trials. OBJECTIVE To evaluate the efficacy of zonisamide for weight loss in obese adults. DESIGN AND SETTING Sixteen-week randomized, double-blin...

Nine patients with refractory partial seizures were evaluated in a pilot study of a new anticonvulsant compound, zonisamide (1,2-benzisoxazole-3-methanesulfonamide; CI-912). Cognitive functioning was evaluated prior to treatment with zonisamide and repeated after 12 and 24 weeks of treatment with zonisamide. At minimum steady-state plasma concentrations greater than 30 micrograms/ml, zonisamide...

Zonisamide is an antiepileptic drug that acts on voltage-sensitive sodium and calcium channels, with a modulatory effect on GABA-mediated neuronal inhibition and an inhibitory effect on carbonic anhydrase. It is used mainly for the treatment of partial seizures, and is generally well tolerated at therapeutic doses. The most common reported adverse effects are somnolence, anorexia, dizziness, an...

An isocratic, selective, and accurate Ion pair reversed phase liquid chromatographic method of analysis of Furosemide and Zonisamide both as a bulk drug and formulations was developed and validated. An ODS chromatographic column (250mmx4.6mm, 5μm) was used for the separation. The mobile phase consisted of a mixture of methanol and Tetrabutyl ammonium hydrogen sulphate (TBHS) 0.035 molar aqueous...

Dr. Yamauchi has pointed out that those patients receiving polytherapy did not do as well as those receiving zonisamide monotherapy. He backed up his observations with blood levels of zonisamide for all the groups. I believe that his observations suggest that the zonisamide dose should be higher, unless the side effects become limiting. As this was a retrospective study, detailed analyses were ...

BACKGROUND Additional options are needed for monotherapy treatment of adults newly diagnosed with partial epilepsy. This trial compares the efficacy and tolerability of once-daily zonisamide with twice-daily controlled-release carbamazepine monotherapy for such patients. METHODS In this phase 3, randomised, double-blind, parallel-group, non-inferiority trial, adults from 120 centres in Asia, ...

Zonisamide is a benzisoxazole-based compound first synthesized in the early 1970s by the research laboratories of Dainippon Pharmaceutical Company in Osaka, Japan. Identified as an anticonvulsant during exploratory research, zonisamide has since been characterized as having broad-spectrum antiepilepsy and neuroprotective effects. Early clinical studies in Japan demonstrated that zonisamide has ...

objectives this study evaluates the efficacy and safety of zonisamide compared with sodium valproate in the management of migraine headaches. patients and methods in the current double-blind, parallel, randomized, controlled trial, 96 patients with a migraine diagnosis based on the international headache society (his) criteria were selected. they were divided randomly into two groups; the case ...